Global
   
Include All CSL Behring Country Sites

Newsroom 2007

2007 Releases

Also in this section

15/10/2007
Minister for Innovation Opens CSL Biopharmaceutical Formulation Centre and Launches New Victorian Biotechnology Strategy
The Hon Gavin Jennings MLC, Victorian Minister for Innovation today officially opened the new Biopharmaceutical Formulation Centre located at CSL Limited in Parkville, Victoria. More.

01/10/2007
U.S. Food and Drug Administration approves CSL influenza virus vaccine, for marketing in the U.S.
CSL Limited, one of the world’s leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has approved its influenza virus vaccine, to be known as Afluria® in the U.S., for active immunisation to prevent influenza disease caused by influenza virus types A and B present in the vaccine in adults 18 years and older. Today’s approval marks CSL’s first entry into the U.S. influenza vaccine market. More.

14/09/2007
Proposed 3 for 1 Share Split
As previously announced, CSL Limited is proposing to subdivide its issued capital on the basis that every one (1) fully paid ordinary share (each a Share) be subdivided into three (3) fully paid ordinary shares (the Share Split), and that options and performance rights on issue be adjusted in accordance with the Listing Rules. More.

22/08/2007
Full Year Results for 2007
CSL Limited today announced its operating result for the full year ended 30 June 2007. More.

17/08/2007
Uptake of Free Cervical Cancer Vaccines Exceeds Expectations
Uptake of Australia’s cervical cancer vaccine through the National Immunisation Program in secondary schools has been highly successful, CSL Limited said today. Amongst the eligible school-based population, vaccine distribution and usage is running at levels not previously achieved in other vaccination programs in this age group. In some states the uptake rate has been as high as 80-90%. CSL has confirmed that in spite of the greater than expected demand, it is able to supply the full needs of the program without difficulty. More.

13/04/2007
CSL Half Year Financial Report 2006/07
Strong profit growth in the first half of the year reflected a solid trading performance by CSL Behring through increased sales and better operating margins. More.

27/03/2007
CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
CSL Limited today announced results from a study published in the Journal of the American Medical Association that suggest infusions of a novel new drug, CSL-111, to acutely raise HDL (“good” cholesterol) levels, may reduce the amount of plaque in the coronary arteries of patients with a recent episode of acute coronary syndrome (ACS). More.

21/02/2007
CSL Half Year Results Announcement for 2006/07
CSL Limited today announced a profit after tax of $257 million for the six months ended 31 December 2006, up 46% when compared to the six months ended 31 December 2005. More.

02/02/2007
CSL Secures Long Term Supply of Helixate from Bayer
CSL Limited announced today that it had concluded an agreement with Sanofi-Aventis that had facilitated an extension of the arrangements with Bayer for the supply of Helixate FS, CSL Behring’s recombinant Factor VIII product. CSL advised that the previous agreement with Bayer on Helixate FS would have expired in 2009, with the new arrangement securing supply for a further eight years until the end of 2017. CSL reported that in the last financial year, Helixate FS generated revenues of US$340 million. More.

30/01/2007
CSL to file Pandemic Vaccine Dossier with the Therapeutic Goods Administration (TGA)
CSL Limited, Australia’s leading biopharmaceutical company, has today announced it has new data from its pandemic influenza vaccine clinical trial program. These results will enable submission of a dossier to the TGA for the registration of a pandemic influenza vaccine. The latest clinical studies confirm that two doses of 30 micrograms of antigen with the addition of an aluminium adjuvant or immune stimulant, are required to produce a strong immune response against the H5N1 bird flu virus. More.